Research advance in progesterone therapy for endometrial cancer
10.12092/j.issn.1009-2501.2024.02.013
- Author:
Liyi ZHANG
1
;
Zifen GUO
1
Author Information
1. Institute of Pharmacy and Pharmacology, School of Pharmaceutical Science, Hengyang Medical College, University of South China
- Publication Type:Journal Article
- Keywords:
clinical application;
endometrial cancer;
progesterone;
progesterone resistance
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(2):230-235
- CountryChina
- Language:Chinese
-
Abstract:
Endometrial cancer originates from the endometrium and is one of the common gynecologic malignancies, with its incidence and mortality rate increasing year by year. Although endometrial cancer is more prevalent in the peri- and postmenopausal female population, it has been an evident trend in recent years towards younger patients. For young patients who have not yet given birth but intend to do so, the application of progestins in endometrial cancer treatment has made significant progress in clinical practice. Considering the existence of large individual differences and unclear mechanisms of action in the clinical application of progestins, this paper aims to provide an overview of the current clinical application status, efficacy, hormone resistance, and its mechanisms in the context of hormone therapy.
